Some of the executive pay rankings are predictable, like Johnson & Johnson's CEO, regardless who's in the job. What's not guaranteed is that the chairman of a generics maker in hot water with the U.S. government and American parents—Mylan's Robert Coury—would step off the company’s employee roster and into the nonexecutive chairman’s job and reap a $97 million package with the move.
On its annual list of the world’s 100 top CEOs, Harvard Business Review tagged 5 biopharma execs--and one, Novo Nordisk CEO Lars Rebien Sørensen, took the No. 1 slot for the second year in a row. Thing is, two of those 5 are on their way out.